迈得医疗(688310) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was CNY 74,220,852.42, representing a year-on-year increase of 2.08%[5] - The net profit attributable to shareholders decreased by 21.61% to CNY 10,513,161.20[5] - Net profit for Q1 2024 was CNY 9,614,159.23, a decrease of 38.5% from CNY 15,623,627.82 in Q1 2023[23] - The company reported a total profit of CNY 10,488,149.85 for Q1 2024, down from CNY 18,750,630.03 in Q1 2023, a decline of 44.5%[23] - Other comprehensive income after tax for Q1 2024 was CNY 174,622.57, compared to a loss of CNY 63,413.86 in Q1 2023[23] Cash Flow - The net cash flow from operating activities fell significantly by 75.73% to CNY 10,344,617.70[6] - Cash received from sales of goods and services was CNY 103,629,381.64 in Q1 2024, a decrease of 17.7% from CNY 125,874,771.07 in Q1 2023[26] - Total cash inflow from operating activities amounted to $134,126,952.06, while cash outflow was $123,782,334.36, resulting in a net increase of $10,344,617.70[27] - The net cash flow from investment activities was -$23,828,213.47, compared to -$54,165,252.47 in the previous year, indicating an improvement[27] - The ending balance of cash and cash equivalents was $254,292,535.79, up from $209,923,467.15 in the previous year[28] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,110,516,301.81, a decrease of 3.42% from the end of the previous year[6] - The total current assets were reported at RMB 681,773,053.34, down from RMB 720,324,715.93, indicating a decrease of about 5.3%[17] - The total liabilities decreased to CNY 160,002,589.04 in Q1 2024 from CNY 209,601,710.61 in Q1 2023, a reduction of 23.7%[19] - The total equity increased to CNY 950,513,712.77 in Q1 2024 from CNY 940,257,051.02 in Q1 2023, showing a growth of 1.3%[19] Research and Development - Research and development expenses totaled CNY 9,880,803.80, an increase of 31.44% compared to the previous year[6] - R&D expenses accounted for 13.31% of operating revenue, up by 2.97 percentage points[6] - Research and development expenses increased to CNY 9,880,803.80 in Q1 2024, compared to CNY 7,517,084.03 in Q1 2023, reflecting a growth of 31.5%[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 4,480[12] - The largest shareholder, Lin Junhua, holds 47.42% of the shares, totaling 55,980,400 shares[12] - The company did not report any significant changes in shareholder structure or related party transactions during the quarter[14] Other Financial Metrics - The weighted average return on net assets was 1.17%, down by 0.45 percentage points[6] - Basic earnings per share for Q1 2024 were CNY 0.09, down from CNY 0.11 in Q1 2023[24] - The company reported a significant drop in receivables financing, which decreased to RMB 32,962,046.45 from RMB 63,482,213.11, a decline of approximately 48%[17] - The company’s goodwill remained stable at RMB 10,423,445.72, unchanged from the previous reporting period[17]